STOCK TITAN

[Form 4] Treace Medical Concepts, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Mark Hair, Chief Financial Officer of Treace Medical Concepts (TMCI), reported a change in beneficial ownership of common stock on 08/09/2025. The Form 4 records a disposition of 22,212 shares with a transaction code labeled "F" and a reported transaction price of $0. After the reported transaction the filing shows Mr. Hair beneficially owns 518,964 shares directly; that total expressly includes 421,228 restricted stock units. The filing discloses the magnitude of the ownership change but does not provide explanation for the transaction code or the zero price.

Mark Hair, Chief Financial Officer di Treace Medical Concepts (TMCI), ha segnalato una variazione nella titolarità beneficiaria delle azioni ordinarie il 08/09/2025. Nel Form 4 risulta una cessione di 22,212 azioni con codice di transazione "F" e prezzo riportato di $0. Dopo l'operazione il documento indica che il sig. Hair detiene beneficiariamente 518,964 azioni direttamente; tale totale include espressamente 421,228 unità di azioni vincolate. Il filing mostra l'entità della variazione di possesso ma non fornisce spiegazioni sul codice di transazione né sul prezzo nullo.

Mark Hair, director financiero de Treace Medical Concepts (TMCI), informó un cambio en la propiedad beneficiaria de acciones ordinarias el 08/09/2025. El Form 4 registra una disposición de 22,212 acciones con un código de transacción "F" y un precio informado de $0. Tras la operación, la presentación indica que el Sr. Hair posee beneficiariamente 518,964 acciones de forma directa; ese total incluye expresamente 421,228 unidades de acciones restringidas. El documento revela la magnitud del cambio de propiedad pero no explica el código de transacción ni el precio cero.

Treace Medical Concepts (TMCI)의 최고재무책임자(CFO)인 Mark Hair는 08/09/2025에 보통주에 대한 실질적 소유권 변동을 신고했습니다. Form 4에는 거래 코드 "F"로 표기된 22,212주의 처분과 신고된 거래 가격 $0가 기재되어 있습니다. 신고서에 따르면 해당 거래 후 Hair 씨는 직접적으로 518,964주를 실질적으로 보유하고 있으며, 이 총액에는 421,228개의 제한된 주식 단위가 명시적으로 포함되어 있습니다. 해당 서류는 소유권 변동의 규모는 공개했지만 거래 코드나 0달러 가격에 대한 설명은 제공하지 않습니다.

Mark Hair, directeur financier de Treace Medical Concepts (TMCI), a déclaré un changement de propriété bénéficiaire d'actions ordinaires le 08/09/2025. Le Form 4 enregistre une cession de 22,212 actions avec un code de transaction "F" et un prix déclaré de $0. Après la transaction déclarée, le dépôt indique que M. Hair possède bénéficiairement 518,964 actions en direct ; ce total inclut expressément 421,228 unités d'actions restreintes. Le dépôt révèle l'ampleur du changement de détention mais ne fournit aucune explication sur le code de transaction ni sur le prix nul.

Mark Hair, Chief Financial Officer von Treace Medical Concepts (TMCI), meldete am 08/09/2025 eine Veränderung seines wirtschaftlichen Anteils an Stammaktien. Im Form 4 ist eine Veräußerung von 22,212 Aktien mit dem Transaktionscode "F" und einem gemeldeten Transaktionspreis von $0 verzeichnet. Nach der gemeldeten Transaktion hält Herr Hair wirtschaftlich direkt 518,964 Aktien; diese Summe umfasst ausdrücklich 421,228 Restricted Stock Units. Die Meldung gibt das Ausmaß der Eigentumsänderung an, liefert jedoch keine Erklärung für den Transaktionscode oder den Nullpreis.

Positive
  • Substantial retained ownership: beneficial ownership remains 518,964 shares after the reported transaction.
  • Significant RSU holdings: the filing explicitly includes 421,228 restricted stock units, indicating continued equity alignment.
Negative
  • Disposition reported: the filing records a 22,212-share disposition on 08/09/2025.
  • Price recorded as $0: the transaction is shown with a reported price of $0 and the filing does not explain the nature of the transfer or the transaction code "F".

Insights

Insider reported a modest disposition; holding remains sizable and, absent context, likely neutral for valuation.

The Form 4 shows an officer-level transaction dated 08/09/2025 in which 22,212 shares were recorded with transaction code "F" and a price of $0. Beneficial ownership after the transaction is listed at 518,964 shares, including 421,228 restricted stock units. From a financial perspective the disclosed sale reduces the insider's liquid share count but leaves a substantial residual stake, suggesting continued alignment with shareholder outcomes. The filing supplies transaction size and resulting ownership but provides no rationale or market context, limiting assessment of immediate market impact.

Officer-level disposition disclosed with large RSU balance; disclosure is straightforward but lacks explanatory detail.

The filing identifies Mark Hair as an officer and Chief Financial Officer and reports a change in common stock holdings on 08/09/2025. The record lists a 22,212-share disposition and a post-transaction direct ownership of 518,964 shares, which includes 421,228 restricted stock units. The transaction is reported with code "F" and a price of $0, information the form includes but does not contextualize. For governance purposes this is routine insider disclosure that meets reporting requirements; however, the absence of explanatory detail about transaction type limits stakeholders' ability to evaluate motives or implications.

Mark Hair, Chief Financial Officer di Treace Medical Concepts (TMCI), ha segnalato una variazione nella titolarità beneficiaria delle azioni ordinarie il 08/09/2025. Nel Form 4 risulta una cessione di 22,212 azioni con codice di transazione "F" e prezzo riportato di $0. Dopo l'operazione il documento indica che il sig. Hair detiene beneficiariamente 518,964 azioni direttamente; tale totale include espressamente 421,228 unità di azioni vincolate. Il filing mostra l'entità della variazione di possesso ma non fornisce spiegazioni sul codice di transazione né sul prezzo nullo.

Mark Hair, director financiero de Treace Medical Concepts (TMCI), informó un cambio en la propiedad beneficiaria de acciones ordinarias el 08/09/2025. El Form 4 registra una disposición de 22,212 acciones con un código de transacción "F" y un precio informado de $0. Tras la operación, la presentación indica que el Sr. Hair posee beneficiariamente 518,964 acciones de forma directa; ese total incluye expresamente 421,228 unidades de acciones restringidas. El documento revela la magnitud del cambio de propiedad pero no explica el código de transacción ni el precio cero.

Treace Medical Concepts (TMCI)의 최고재무책임자(CFO)인 Mark Hair는 08/09/2025에 보통주에 대한 실질적 소유권 변동을 신고했습니다. Form 4에는 거래 코드 "F"로 표기된 22,212주의 처분과 신고된 거래 가격 $0가 기재되어 있습니다. 신고서에 따르면 해당 거래 후 Hair 씨는 직접적으로 518,964주를 실질적으로 보유하고 있으며, 이 총액에는 421,228개의 제한된 주식 단위가 명시적으로 포함되어 있습니다. 해당 서류는 소유권 변동의 규모는 공개했지만 거래 코드나 0달러 가격에 대한 설명은 제공하지 않습니다.

Mark Hair, directeur financier de Treace Medical Concepts (TMCI), a déclaré un changement de propriété bénéficiaire d'actions ordinaires le 08/09/2025. Le Form 4 enregistre une cession de 22,212 actions avec un code de transaction "F" et un prix déclaré de $0. Après la transaction déclarée, le dépôt indique que M. Hair possède bénéficiairement 518,964 actions en direct ; ce total inclut expressément 421,228 unités d'actions restreintes. Le dépôt révèle l'ampleur du changement de détention mais ne fournit aucune explication sur le code de transaction ni sur le prix nul.

Mark Hair, Chief Financial Officer von Treace Medical Concepts (TMCI), meldete am 08/09/2025 eine Veränderung seines wirtschaftlichen Anteils an Stammaktien. Im Form 4 ist eine Veräußerung von 22,212 Aktien mit dem Transaktionscode "F" und einem gemeldeten Transaktionspreis von $0 verzeichnet. Nach der gemeldeten Transaktion hält Herr Hair wirtschaftlich direkt 518,964 Aktien; diese Summe umfasst ausdrücklich 421,228 Restricted Stock Units. Die Meldung gibt das Ausmaß der Eigentumsänderung an, liefert jedoch keine Erklärung für den Transaktionscode oder den Nullpreis.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hair Mark

(Last) (First) (Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE

(Street)
PONTE VEDRA FL 32081

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/09/2025 F 22,212 D $0 518,964(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 421,228 restricted stock units.
/s/ Lisa Taylor as Attorney-in-fact for Mark Hair 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Mark Hair report for TMCI?

He reported a disposition of 22,212 shares of TMCI common stock on 08/09/2025.

How many TMCI shares does Mark Hair beneficially own after the reported transaction?

518,964 shares beneficially owned following the reported transaction, reported as direct ownership.

Does the reported ownership include restricted stock units (RSUs)?

Yes. The filing states the total includes 421,228 restricted stock units.

What is the reporting person's role at Treace Medical Concepts (TMCI)?

Mark Hair is reported as an officer and the Chief Financial Officer.

Were any derivative securities disclosed in this Form 4?

No derivative securities were reported in Table II of the filing.

Was the Form 4 filed individually or jointly?

The form was filed by one reporting person (individual filing).
Treace Medical Concepts, Inc.

NASDAQ:TMCI

TMCI Rankings

TMCI Latest News

TMCI Latest SEC Filings

TMCI Stock Data

435.89M
46.88M
25.81%
62.39%
4.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA